BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Prognica Labs inks strategic partnership with Pinnacology to advance novel intranasal anxiety therapy

October 25, 2026 | News

Collaboration combines AI-driven drug discovery, pharmaceutical development and commercialisation expertise

Prognica Labs, a Dubai-headquartered AI-driven life sciences company, and Pinnacology Research & Development, an India-based pharmaceutical research company, have announced a strategic co-development and commercialisation partnership to advance an investigational intranasal microemulsion therapy for anxiety.

The collaboration aims to translate promising natural-product research into a scientifically validated pharmaceutical development programme, combining Pinnacology's formulation research and technical expertise with Prognica's AI-enabled drug discovery platform, translational R&D capabilities, clinical development intelligence and international commercialisation network.

Anxiety disorders represent one of the world's most prevalent mental health challenges. According to the World Health Organization (WHO), approximately 359 million people worldwide were living with anxiety disorders in 2021, highlighting the substantial need for accessible and effective treatment options.

The commercial opportunity is also significant. Industry market research cited in Pinnacology's development presentation estimates the global anxiety disorders treatment market at approximately $12.3 billion in 2025, with projections reaching $17.6 billion by 2035, representing an estimated compound annual growth rate of 3.6%.

The proposed therapy combines naturally derived phytochemicals, including flavan-3-ols, with aromatic resin extracts in an intranasal microemulsion formulation.

The research identified potential interactions involving neurological targets such as MAOA, SLC6A4 and COMT and reported encouraging findings in preclinical behavioral studies.

The intranasal delivery strategy will investigate whether the formulation can achieve suitable drug exposure, acceptable nasal tolerability and a clinically useful onset of action.

India is expected to serve as an initial development focus, with opportunities for subsequent expansion into GCC and other international markets, subject to regulatory approvals and clinical validation.